|
JO3425B1
(ar)
|
2013-07-15 |
2019-10-20 |
Novartis Ag |
مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b
|
|
EP3340982B1
(en)
|
2015-08-26 |
2021-12-15 |
Achillion Pharmaceuticals, Inc. |
Compounds for treatment of immune and inflammatory disorders
|
|
AR106018A1
(es)
|
2015-08-26 |
2017-12-06 |
Achillion Pharmaceuticals Inc |
Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
|
|
JP7054529B2
(ja)
|
2016-06-21 |
2022-04-14 |
エックス４ ファーマシューティカルズ， インコーポレイテッド |
Ｃｘｃｒ４阻害剤およびその使用
|
|
CA3027500A1
(en)
*
|
2016-06-21 |
2017-12-28 |
X4 Pharmaceuticals, Inc. |
Cxcr4 inhibitors and uses thereof
|
|
CN109414441A
(zh)
*
|
2016-06-27 |
2019-03-01 |
艾其林医药公司 |
治疗医学障碍的喹唑啉和吲哚化合物
|
|
CN113444046B
(zh)
*
|
2016-07-20 |
2023-10-27 |
纳莹(上海)生物科技有限公司 |
一种荧光探针及其制备方法和用途
|
|
KR102632860B1
(ko)
|
2017-03-01 |
2024-02-02 |
아칠리온 파르마세우티칼스 인코포레이티드 |
의학적 장애의 치료를 위한 아릴, 헤테로아릴, 및 헤테로사이클릭 약학적 화합물
|
|
HUE066356T2
(hu)
|
2017-08-24 |
2024-07-28 |
Novo Nordisk As |
GLP-1 készítmények és alkalmazásaik
|
|
BR112020003737A2
(pt)
*
|
2017-08-31 |
2020-09-01 |
Novartis Ag |
usos de derivados de piperidinil-indol
|
|
JP2021530505A
(ja)
*
|
2018-07-16 |
2021-11-11 |
ノバルティス アーゲー |
フェニルピペリジニルインドール誘導体を調製する化学的プロセス
|
|
US20230022157A1
(en)
|
2018-08-20 |
2023-01-26 |
Achillion Pharmaceuticals, Inc. |
Pharmaceutical compounds for the treatment of complement factor d medical disorders
|
|
US11814363B2
(en)
|
2018-09-06 |
2023-11-14 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of danicopan
|
|
EP3846803A4
(en)
|
2018-09-06 |
2022-08-10 |
Achillion Pharmaceuticals, Inc. |
Macrocyclic compounds for the treatment of medical disorders
|
|
EP3856164B1
(en)
|
2018-09-25 |
2024-08-07 |
Achillion Pharmaceuticals, Inc. |
Morphic forms of complement factor d inhibitors
|
|
CA3125886A1
(en)
|
2019-01-11 |
2020-07-16 |
Novartis Ag |
Anti-cd40 antibodies for use in treatment of hidradenitis suppurativa
|
|
EP3908279B1
(en)
|
2019-01-11 |
2024-08-28 |
Novartis AG |
Lta4h inhibitor for the treatment or prevention of hidradenitis suppurativa
|
|
PE20221575A1
(es)
|
2020-02-18 |
2022-10-06 |
Novo Nordisk As |
Formulaciones farmaceuticas
|
|
CN115362162A
(zh)
|
2020-02-20 |
2022-11-18 |
艾其林医药公司 |
用于治疗补体因子d介导的障碍的杂芳基化合物
|
|
KR20250048392A
(ko)
|
2020-05-18 |
2025-04-08 |
노파르티스 아게 |
Lnp023의 결정질 형태
|
|
EP4181922A1
(en)
|
2020-07-16 |
2023-05-24 |
Novartis AG |
Methods of using factor b inhibitors
|
|
US11951101B2
(en)
|
2020-07-16 |
2024-04-09 |
Novartis Ag |
Methods of using factor B inhibitors
|
|
US20230286947A1
(en)
*
|
2020-08-07 |
2023-09-14 |
Shanghai Meiyue Biotech Development Co. Ltd |
Complement factor b inhibitor, and pharmaceutical composition, preparation method and use thereof
|
|
US20230331710A1
(en)
*
|
2020-08-07 |
2023-10-19 |
Shanghai Meiyue Biotech Development Co. Ltd |
Heterocyclic compound, preparation method and use thereof
|
|
CA3193488A1
(en)
|
2020-09-23 |
2022-03-31 |
Jason Allan Wiles |
Pharmaceutical compounds for the treatment of complement mediated disorders
|
|
CN119798256A
(zh)
*
|
2020-12-30 |
2025-04-11 |
江苏恒瑞医药股份有限公司 |
含氮桥杂环化合物、其制备方法及其在医药上的应用
|
|
JP7641388B2
(ja)
*
|
2020-12-30 |
2025-03-06 |
エス－インフィニティ ファーマシューティカルズ カンパニー リミテッド |
一連のピペリジン置換安息香酸系化合物及びその使用
|
|
CA3205097A1
(en)
*
|
2021-01-14 |
2022-07-21 |
Jason Allan Wiles |
Macrocycle complement factor b inhibitors
|
|
US20240217953A1
(en)
*
|
2021-04-16 |
2024-07-04 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
Bicyclic substituted aromatic carboxylic acid compounds
|
|
JP2024517234A
(ja)
*
|
2021-05-07 |
2024-04-19 |
ノバルティス アーゲー |
非典型溶血性尿毒症症候群の処置のためのイプタコパン
|
|
MX2023014274A
(es)
*
|
2021-06-03 |
2024-04-22 |
Chinook Therapeutics Inc |
Compuestos indol sustituidos y metodos de uso de los mismos.
|
|
JP2024522769A
(ja)
|
2021-06-18 |
2024-06-21 |
ノバルティス アーゲー |
自己免疫性血液学的疾患を治療する方法
|
|
EP4362933A4
(en)
*
|
2021-06-30 |
2025-06-04 |
Apellis Pharmaceuticals, Inc. |
COMPLEMENT INHIBITION
|
|
CA3229360A1
(en)
|
2021-08-18 |
2023-02-23 |
Chen Zhang |
Benzo nitrogen-containing heteroaromatic ring derivative and use thereof in medicine
|
|
JP2024530344A
(ja)
*
|
2021-09-07 |
2024-08-16 |
ノバルティス アーゲー |
加齢黄斑変性の処置のためのｂ因子阻害剤の使用
|
|
EP4423076A4
(en)
*
|
2021-10-27 |
2026-01-07 |
Hansoh Bio Llc |
PIPERIDINYL INDOLE DERIVATIVES, THEIR PREPARATION PROCESSES AND MEDICAL USES
|
|
CR20240300A
(es)
|
2022-01-24 |
2024-08-23 |
Novartis Ag |
Derivados espirocíclicos de piperidinilo como inhibidores del factor b del complemento y usos de los mismos.
|
|
EP4471021A4
(en)
*
|
2022-01-26 |
2025-04-30 |
Shanghai Meiyue Biotech Development Co., Ltd. |
Salt type and crystal form of complement factor b inhibitor, and preparation method therefor and application thereof
|
|
TW202342048A
(zh)
|
2022-02-28 |
2023-11-01 |
瑞士商諾華公司 |
使用ｌｏｕ０６４治療化膿性汗腺炎之方法
|
|
KR20240155291A
(ko)
|
2022-03-04 |
2024-10-28 |
노파르티스 아게 |
루푸스 신염 치료를 위한 입타코판의 용도
|
|
AR128931A1
(es)
|
2022-04-01 |
2024-06-26 |
Novartis Ag |
Inhibidores del factor b del complemento y usos de los mismos
|
|
WO2023246677A1
(zh)
*
|
2022-06-20 |
2023-12-28 |
深圳信立泰药业股份有限公司 |
一种吲哚-苯基哌啶化合物及其制备方法与应用
|
|
CN119546585A
(zh)
*
|
2022-06-23 |
2025-02-28 |
上海济煜医药科技有限公司 |
吲哚化合物的制备、应用及用途
|
|
US20250382287A1
(en)
|
2022-06-30 |
2025-12-18 |
Jiangsu Hengrui Pharmaceuticals Co., Ltd. |
Pharmaceutically acceptable salt and crystal form of nitrogen-containing bridge heterocyclic derivative, and method for preparing same
|
|
CN117327070A
(zh)
*
|
2022-06-30 |
2024-01-02 |
江苏恒瑞医药股份有限公司 |
一种含氮桥杂环衍生物的晶型及其制备方法
|
|
JP2025530766A
(ja)
*
|
2022-08-29 |
2025-09-17 |
シーエムエス リサーチ アンド ディベロップメント ピーティーイー リミテッド |
窒素含有架橋複素環化合物及びその製造方法
|
|
WO2024049977A1
(en)
*
|
2022-08-31 |
2024-03-07 |
Chinook Therapeutics, Inc. |
Substituted indole compounds and methods of use thereof
|
|
JP2025530222A
(ja)
|
2022-09-10 |
2025-09-11 |
江▲蘇▼豪森▲薬▼▲業▼集▲団▼有限公司 |
２－置換ピペリジン誘導体、その製造方法及び医薬的用途
|
|
EP4617266A1
(en)
|
2022-11-11 |
2025-09-17 |
Shanghai Yisheng Biopharmaceutical company Limited |
Piperidine-substituted benzoic acid compound, and pharmaceutical composition and use thereof
|
|
KR20250107882A
(ko)
*
|
2022-11-14 |
2025-07-14 |
노파르티스 파르마 아게 |
보체 인자 b 억제제의 고체 형태
|
|
TWI869080B
(zh)
*
|
2022-11-29 |
2025-01-01 |
大陸商上海濟煜醫藥科技有限公司 |
苯並螺環吲哚化合物的製備及用途
|
|
WO2024141011A1
(zh)
*
|
2022-12-31 |
2024-07-04 |
深圳晶泰科技有限公司 |
补体因子b抑制剂及其药物组合物和应用
|
|
WO2024148274A1
(en)
*
|
2023-01-05 |
2024-07-11 |
Apellis Pharmaceuticals, Inc. |
Complement inhibition
|
|
EP4670719A1
(en)
|
2023-02-22 |
2025-12-31 |
Haisco Pharmaceutical Group Co., Ltd. |
PHARMACEUTICAL COMPOSITION OF A HETEROAROMATIC BENZO-NITROGEN RING DERIVATIVE AND ITS USE IN MEDICINE
|
|
WO2024176169A1
(en)
|
2023-02-23 |
2024-08-29 |
Novartis Ag |
Methods of using factor b inhibitors
|
|
TW202438499A
(zh)
*
|
2023-03-21 |
2024-10-01 |
大陸商上海美悦生物科技發展有限公司 |
螺環類化合物及其藥物組合物、製備方法和用途
|
|
WO2024222852A1
(zh)
|
2023-04-27 |
2024-10-31 |
上海翰森生物医药科技有限公司 |
一种哌啶基吲哚化合物的盐及其制备方法
|
|
AU2024290587A1
(en)
|
2023-07-04 |
2026-02-19 |
Sitala Bio Ltd |
2-(1h-indol-4-yl)methyl)-isoindoline derivatives as factor b inhibitors
|
|
WO2025008451A1
(en)
|
2023-07-04 |
2025-01-09 |
Sitala Bio Ltd |
2-(1h-indol-4-yl)methyl)2h-indazole derivatives as factor b inhibitors
|
|
EP4739667A2
(en)
|
2023-07-06 |
2026-05-13 |
Sitala Bio Ltd |
Indole derivatives with factor b inhibitory activity
|
|
WO2025008517A1
(en)
|
2023-07-06 |
2025-01-09 |
Sitala Bio Ltd |
Indole derivatives with factor b inhibitory activity
|
|
TWI896250B
(zh)
|
2023-07-26 |
2025-09-01 |
大陸商上海美悦生物科技發展有限公司 |
螺環烯基類或氮雜烯基類化合物及其藥物組合物、製備方法和用途
|
|
AU2024332373A1
(en)
|
2023-08-25 |
2025-10-23 |
Novartis Ag |
Methods of using factor b inhibitors
|
|
CN121925409A
(zh)
|
2023-09-29 |
2026-04-24 |
诺华股份有限公司 |
补体因子b抑制剂及其用途
|
|
WO2025083621A1
(en)
|
2023-10-20 |
2025-04-24 |
Novartis Ag |
Treatment of hidradenitis suppurativa using anti-baff-r antibodies
|
|
TW202535375A
(zh)
*
|
2023-12-05 |
2025-09-16 |
大陸商西藏海思科製藥有限公司 |
苯並氮雜芳環衍生物在治療補體因數b介導的疾病中的用途
|
|
WO2025148628A1
(zh)
*
|
2024-01-10 |
2025-07-17 |
河北以岭医药研究院有限公司 |
哌啶基吲哚衍生物及其制备方法和应用
|
|
WO2025172535A1
(en)
|
2024-02-15 |
2025-08-21 |
Sitala Bio Ltd |
Indole and benzimidazole compounds as factor b inhibitors
|
|
WO2025172910A1
(en)
|
2024-02-16 |
2025-08-21 |
Novartis Ag |
Factor b inhibitors for treatment of anca-associated vasculitis
|
|
WO2025185734A1
(zh)
*
|
2024-03-08 |
2025-09-12 |
江苏豪森药业集团有限公司 |
一种多元螺环化合物的盐及其晶型、其制备方法和医药用途
|
|
CN121532400A
(zh)
*
|
2024-05-11 |
2026-02-13 |
礼邦医药(香港)有限公司 |
补体因子b抑制剂
|
|
WO2025252133A1
(zh)
*
|
2024-06-07 |
2025-12-11 |
润尔眼科药物（广州）有限公司 |
一种含吲哚基团的化合物及其用途
|
|
WO2025256647A1
(zh)
*
|
2024-06-14 |
2025-12-18 |
润尔眼科药物（广州）有限公司 |
化合物及其医药用途
|
|
WO2026002007A1
(zh)
*
|
2024-06-25 |
2026-01-02 |
珠海联邦制药股份有限公司 |
补体因子b抑制剂及其药物组合物和应用
|
|
WO2026003809A1
(en)
|
2024-06-29 |
2026-01-02 |
Assia Chemical Industries Ltd. |
Solid state forms of iptacopan hydrochloride
|
|
WO2026008074A1
(zh)
*
|
2024-07-05 |
2026-01-08 |
南京正大天晴制药有限公司 |
补体因子b抑制剂的晶型、其制备方法及用途
|
|
WO2026069246A1
(en)
|
2024-09-30 |
2026-04-02 |
Novartis Ag |
Complement factor b inhibitors and uses thereof
|
|
WO2026086939A1
(zh)
*
|
2024-10-25 |
2026-04-30 |
上海美悦生物科技发展有限公司 |
杂环化合物在制备预防或治疗IgA肾病的药物中的用途
|
|
WO2026093943A1
(en)
|
2024-10-31 |
2026-05-07 |
Novartis Ag |
Chemical process for preparing phenylpiperidinyl indole derivatives
|